CEO, Pharmaceutical Services
And Active Ingredients
Vice President and
Head- US & Europe
Vice President and
Region Head - US
Executive VP and Global Head Supply,
Demand Planning and Delivery
Vice President and
Region Head - Europe
Associate VP - US
Director, Mexico &
Central America
Associate VP - US
CEO, Pharmaceutical Services
And Active Ingredients
Vice President and
Head- US & Europe
Vice President and
Region Head - US
Executive VP and Global Head Supply,
Demand Planning and Delivery
Vice President and
Region Head - Europe
Associate VP - US
Director, Mexico &
Central America
Associate VP - US
DCAT Week 2023 is the premier global event for companies engaged in the bio/pharmaceutical manufacturing value chain. Hosted by the Drug, Chemical & Associated Technologies Association (DCAT), this annual event brings together innovator and generic drug manufacturers, suppliers of ingredients, development and manufacturing services, and related technologies for four days of networking, education, and business development.
This year, DCAT Week will be held on March 20-23, 2023, in New York City. The event features a robust program of educational sessions and workshops and an exhibition floor showcasing the latest products, services, and technologies from leading companies in the industry.
At DCAT Week 2023, attendees will have the opportunity to connect with industry leaders and experts, learn about the latest trends and advancements in bio/pharmaceutical manufacturing, and explore new business opportunities. Whether you're a manufacturer, supplier, or service provider, DCAT Week is the perfect platform to showcase your company and connect with potential partners and customers.
In addition to the exhibition and educational sessions, DCAT Week 2023 also features networking events and receptions, providing attendees with ample opportunities to connect with their peers and expand their professional networks. Don't miss the chance to be a part of this premier industry event. Schedule your meeting today and join us at DCAT Week 2023 in New York City!
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.
Nenhuma informação neste catálogo - incluindo qualquer referência a qualquer produto ou serviço - constitui uma oferta de venda ou deve ser interpretada como uma oferta de venda. Os produtos protegidos por patentes válidas não são oferecidos ou fornecidos para uso comercial. No entanto, as quantidades de pesquisa de tais produtos podem ser oferecidas para fins de submissão regulatória, onde quer que existam tais isenções regulatórias. Os compradores devem fazer sua avaliação independente do cenário de patentes para seus respectivos mercados e serão responsáveis por todas as responsabilidades relacionadas à patente. Os produtos protegidos por patentes válidas na Índia não estão disponíveis para uso comercial, mas estariam disponíveis para os propósitos da Seção 107A.